Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Sports supplement will be classified as a steroid in the coming months, Drug Czar Barry McCaffrey announces at a Citizenship Through Sports Alliance meeting in Arlington, Va. June 26. President Clinton's top drug policy adviser maintains androstenedione fits the criteria to be labeled a steroid in two of the three government tests used to classify hormonal substances. Groups such as the Blue Cross/Blue Shield's Healthy Competition Foundation have asked pro athletes to stop using performance enhancing substances, which gained notoriety due to their use by popular stars such as baseball slugger Mark McGwire, who has since stopped using andro (1"The Tan Sheet" April 3, p. 6)

You may also be interested in...

FDA/DEA Ban Of Andro Sought By Blue Cross & Blue Shield Foundation

A youth sports advocacy group is attempting to halt the sale and use of androstenedione-containing dietary supplements with a dual-pronged initiative aimed at Major League Baseball players and federal regulators, including FDA.

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts